InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma
Orlow I, Sadeghi K, Edmiston S, Kenney J, Lezcano C, Wilmott J, Cust A, Scolyer R, Mann G, Lee T, Burke H, Jakrot V, Shang P, Ferguson P, Boyce T, Ko J, Ngo P, Funchain P, Rees J, O’Connell K, Hao H, Parrish E, Conway K, Googe P, Ollila D, Moschos S, Hernando E, Hanniford D, Argibay D, Amos C, Lee J, Osman I, Luo L, Kuan P, Aurora A, Rothberg BE, Bosenberg M, Gerstenblith M, Thompson C, Bogner P, Gorlov I, Holmen S, Brunsgaard E, Saenger Y, Shen R, Seshan V, Nagore E, Ernstoff M, Busam K, Begg C, Thomas N, Berwick M, Consortium O. InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PLOS ONE 2023, 18: e0269324. PMID: 37011054, PMCID: PMC10069769, DOI: 10.1371/journal.pone.0269324.Peer-Reviewed Original ResearchConceptsEarly-stage melanomaPrimary melanomaMemorial Sloan-Kettering Cancer CenterDisease-specific survivalPredictors of survivalMulti-institutional settingSomatic mutationsPre-established protocolMiRNA expressionScreening failureMulticenter studyCancer CenterDownstream testingLimited tumor tissueNucleic acid qualityClinical databaseMulticenter researchTumor tissueMelanomaTumor samplesFFPE tumorsArchival tissueFFPE tissue blocksTissue blocksSuccess rateValidation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma
Miguez S, Lee R, Chan A, Demkowicz P, Jones B, Long C, Abramson D, Bosenberg M, Sznol M, Kluger H, Goldbaum M, Francis J, Pointdujour-Lim R, Bakhoum M. Validation of the Prognostic Usefulness of the Gene Expression Profiling Test in Patients with Uveal Melanoma. Ophthalmology 2023, 130: 598-607. PMID: 36739981, PMCID: PMC10619207, DOI: 10.1016/j.ophtha.2023.01.020.Peer-Reviewed Original ResearchConceptsMetastasis-free survivalRisk of metastasisClass 2 tumorsAdditional prognostic valueRate of metastasisPrognostic usefulnessTumor sizeTumor characteristicsPrognostic valueUveal melanomaGene expression profile testingMemorial Sloan-Kettering Cancer CenterGEP classificationCox hazard regression analysisYale-New Haven HospitalHazards regression analysisGene expression profiling testsNew Haven HospitalClass 1 tumorsGEP class 2Class 1AMean followTumor thicknessCancer CenterSurveillance protocol